In an era where transparency in healthcare costs is more crucial than ever, RxDC Reporting stands out as a pivotal regulatory requirement that aims to shed light on the complexities of prescription drug pricing. Introduced by the Consolidated Appropriations Act (CAA) of 2021, this mandate requires group health plans and health insurance issuers to disclose detailed information about the prescription drugs they cover and the associated costs. While this requirement offers opportunity for improved public policy, it also creates burden and risk for employers resulting from annual disclosure requirements.
Valhalla Business Advisors is committed to equipping clients with the expertise and tools necessary to navigate the requirements under RxDC. Understanding the scope of the mandate, the specific data required, and the implications of compliance are essential for maintaining regulatory adherence and optimizing health plan operations
What is rxdc?
RxDC Reporting, or Prescription Drug Data Collection Reporting, was established by the Consolidated Appropriations Act (CAA) of 2021. This regulation serves as a crucial component of a broader initiative aimed at enhancing transparency within the healthcare sector, particularly concerning prescription drugs. It mandates that group health plans and health insurance issuers providing group or individual health insurance coverage meticulously report detailed information about the prescription drugs they cover and the associated costs. This initiative not only seeks to shed light on prescription drug pricing but also aims to facilitate better healthcare cost management.
What are the obligations of employers?
The RxDC Reporting requirements extend to a wide range of plan sponsors, encompassing:
- Fully insured, small group plans
- Fully insured, large group plans
- Self-funded (including Level funded), small group plans
- Self-funded (including Level funded), large group plans
It is important to note that there are very few exceptions for reporting; There is no exception for churches or governments; There is no exception for small business.
These stipulations ensure that a broad spectrum of health plans contribute to the transparency and data collection efforts, providing a comprehensive view of the drug pricing landscape across various types of health insurance arrangements.
What data is necessary? Where does data come from?
The information necessary for effective reporting encompasses various aspects of health plan operations and drug pricing strategies. This data is categorized and collected primarily through two specific forms known as the Plan (P) and Drug (D) forms.
- Plan and Drug Information Forms (P and D Forms):
- Plan Form (P): This form collects general information about the health plan, including plan year, types of benefits offered, and the number of plan participants. It serves as a foundational document that outlines the scope and coverage specifics of the health plan.
- Drug Form (D): Focused on the pharmaceutical aspect, this form requires detailed data on prescription drugs covered by the plan, including usage statistics, cost data, and pricing arrangements. It’s instrumental in analyzing the financial impact of drug coverage under the health plan.
- Data from Insurers or Third-Party Administrators (TPAs):
- Insurers and TPAs play a crucial role in the healthcare ecosystem by managing health claims and overseeing the administration of benefits. For RxDC Reporting, they provide essential data on claims, including the volume of transactions, reimbursement rates, and total expenditure on prescribed medications. This data helps in understanding the broader financial implications of drug benefits on health plans.
- Information from Pharmacy Benefit Managers (PBMs):
- PBMs are at the forefront of managing prescription drug benefits and are critical in the negotiation of drug prices and rebates. The information they provide includes detailed pricing structures, rebate agreements, and cost management strategies employed throughout the plan year. This data is vital for assessing the effectiveness of cost-control measures and the overall affordability of drug coverage.
What is new for 2024?
For the year 2024, there are notable updates to the RxDC Reporting requirements that plan sponsors need to be aware of:
- Introduction of a “simplified” calculation method for the average monthly premium, which aims to streamline the reporting process.
- Additional guidelines on calculating premium equivalents, providing clearer directions for plan sponsors.
- Strict enforcement of aggregation restrictions to ensure data accuracy and integrity.
What are the implications for employers? Is there financial liability?
For employers, the implications of RxDC Reporting are significant, both in terms of administrative responsibility and potential financial liability. Employers need to ensure accurate and timely submission of required information to avoid penalties. While there is no direct financial penalty articulated in the statute, failure to comply with reporting requirements can lead to financial penalties arising from ERISA (e.g. $100 per participant per day). Furthermore, the administrative burden of gathering and reporting this data requires adequate resources and systems, potentially leading to increased operational costs.
The Valhalla advantage
At Valhalla Business Advisors, we understand the complexities and challenges associated with RxDC Reporting. Our expertise in navigating these regulatory waters ensures that our clients can fulfill their reporting obligations without undue stress or error. We offer tailored support to manage compliance efficiently, ensuring that all data is accurate, comprehensive, and submitted on time. Let Valhalla Business Advisors be your guide in the intricate landscape of healthcare reporting, where our strategic insights and solutions keep your operations smooth and compliant.
P.S. Thank you to our friends at Savoy Associates for a very informative webinar in April 2024!
APPENDIX
Additional Resources
Sources
Sample Scope of Work
